Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
CAR therapy beyond the CD19 paradigm
Michel Sadelain
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 30, 2017 8:00 AM-10:00 AM
Improving remission durability after CAR T cell therapy for ALL
Terry J Fry
National Cancer Institute, Bethesda, MD, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 30, 2017 8:00 AM-10:00 AM
Title to be announced
Martin Pule
Autolus, London, United Kingdom
from 2017 Molecular Targets and Cancer Therapeutics conference on October 30, 2017 8:00 AM-10:00 AM
Engineering human T cells with non-viral genome targeting
Theodore Roth
University of California, San Francisco, CA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 30, 2017 8:00 AM-10:00 AM
PROTAC-mediated protein degradation: A chemical equivalent of CRISPR
Craig M. Crews
Yale Univ., New Haven, CT, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 30, 2017 10:20 AM-12:30 PM
Block the exits: ABL001 enables dual targeting of BCR-ABL
Andrew Wylie
Novartis, Cambridge, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 30, 2017 10:20 AM-12:30 PM
Targeted inhibition of the ERK pathway: Precision medicine?
Neal Rosen
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 30, 2017 10:20 AM-12:30 PM
Title to be announced
Jeffrey A. Engelman
Novartis, Cambridge, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 30, 2017 10:20 AM-12:30 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8